{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"An adverse event was defined as any untoward medical event that occurred in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs were defined as any AE that occurred at or after the initial administration of study intervention through the day of last dose plus 30 days.","groups":[{"description":"Treatment naive or relapsed/refractory Waldenstrom's Macroglobulinemia (WM) Japanese participants received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity along with rituximab 375 milligrams per square meter (mg/m\\^2) intravenously (IV) weekly for 4 consecutive weeks (Day 1 of Weeks 1 to 4), followed by a second course of once-weekly rituximab for 4 consecutive weeks (from Week 17 to 20) after a 12-week interval.","id":"OG000","title":"Ibrutinib + Rituximab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all enrolled participants who received at least 1 dose of ibrutinib.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to 30 days post last dose of study drug (that is, up to 40.6 months)","title":"Number of Participants With Treatment- Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}